Effect of a Smoking and Alcohol Cessation Intervention Initiated Shortly Before Radical Cystectomy-the STOP-OP Study: A Randomised Clinical Trial.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
11 2022
Historique:
received: 11 11 2021
revised: 02 02 2022
accepted: 15 02 2022
pubmed: 5 3 2022
medline: 15 12 2022
entrez: 4 3 2022
Statut: ppublish

Résumé

Evidence concerning the reduction of postoperative complications due to smoking and alcohol drinking in patients undergoing radical cystectomy is incomplete. To evaluate the efficacy of a 6-wk smoking and/or alcohol cessation intervention, initiated shortly before surgery and continued until 4 wk after, in reducing complications. Between 2014 and 2018, we enrolled 104 patients with high-risk bladder cancer who were daily smokers or consuming at least 3 units of alcohol daily in a multicentre randomised clinical trial. Patients were randomised to a 6-wk intensive smoking and/or alcohol cessation intervention or treatment as usual. The primary endpoint was the number of patients developing any postoperative complication, or death, within 30 d after surgery. The secondary endpoints were successful quitters, health-related quality of life, length of stay, time back to habitual activity, and mortality. An intention-to-treat analysis was applied to evaluate treatment effect. There were some differences in baseline demographic and lifestyle characteristics. Postoperatively, 64% in the intervention group versus 70% in the control group (risk ratio [RR] 0.91, confidence interval [CI] 0.68-1.21, p = 0.51) developed complications. Significantly fewer patients developed three or more complications after 30 d (RR 0.39; CI 0.18-0.84, p = 0.01). The rates of successful quitting were 51% in the intervention group and 27% in the control group (RR 2, CI 1.14-3.51, p = 0.01). The external validity of this trial may be limited because 53% of eligible patients refused participation. Despite a significant effect on the quit rate at completion of the intervention, this multimodal prehabilitation did not show a significant difference regarding our primary outcome postoperative complications. A 6-wk smoking and alcohol cessation intervention in relation to bladder cancer surgery did not reduce postoperative complications, but it was effective in supporting people to quit in the short term.

Sections du résumé

BACKGROUND
Evidence concerning the reduction of postoperative complications due to smoking and alcohol drinking in patients undergoing radical cystectomy is incomplete.
OBJECTIVE
To evaluate the efficacy of a 6-wk smoking and/or alcohol cessation intervention, initiated shortly before surgery and continued until 4 wk after, in reducing complications.
DESIGN, SETTING, AND PARTICIPANTS
Between 2014 and 2018, we enrolled 104 patients with high-risk bladder cancer who were daily smokers or consuming at least 3 units of alcohol daily in a multicentre randomised clinical trial.
INTERVENTION
Patients were randomised to a 6-wk intensive smoking and/or alcohol cessation intervention or treatment as usual.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
The primary endpoint was the number of patients developing any postoperative complication, or death, within 30 d after surgery. The secondary endpoints were successful quitters, health-related quality of life, length of stay, time back to habitual activity, and mortality. An intention-to-treat analysis was applied to evaluate treatment effect.
RESULTS AND LIMITATIONS
There were some differences in baseline demographic and lifestyle characteristics. Postoperatively, 64% in the intervention group versus 70% in the control group (risk ratio [RR] 0.91, confidence interval [CI] 0.68-1.21, p = 0.51) developed complications. Significantly fewer patients developed three or more complications after 30 d (RR 0.39; CI 0.18-0.84, p = 0.01). The rates of successful quitting were 51% in the intervention group and 27% in the control group (RR 2, CI 1.14-3.51, p = 0.01). The external validity of this trial may be limited because 53% of eligible patients refused participation.
CONCLUSIONS
Despite a significant effect on the quit rate at completion of the intervention, this multimodal prehabilitation did not show a significant difference regarding our primary outcome postoperative complications.
PATIENT SUMMARY
A 6-wk smoking and alcohol cessation intervention in relation to bladder cancer surgery did not reduce postoperative complications, but it was effective in supporting people to quit in the short term.

Identifiants

pubmed: 35241394
pii: S2405-4569(22)00050-5
doi: 10.1016/j.euf.2022.02.005
pii:
doi:

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1650-1658

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Susanne Vahr Lauridsen (SV)

Department of Urology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; WHO-CC, Clinical Health Promotion Centre, Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen University Hospitals, Copenhagen, Denmark. Electronic address: Susanne.vahr.lauridsen@regionh.dk.

Thordis Thomsen (T)

Department of Anaesthesiology, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Jørgen Bjerggaard Jensen (JB)

Department of Urology, Aarhus University Hospital, Aarhus, Denmark.

Thomas Kallemose (T)

Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.

Monika Schmidt Behrend (M)

Department of Urology, Herlev Hospital, Herlev, Denmark.

Kirsten Steffensen (K)

Department of Urology, Aalborg University Hospital, Farso, Denmark.

Alicia Martin Poulsen (AM)

Department of Urology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

André Jacobsen (A)

Department of Urology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Urology, Herlev Hospital, Herlev, Denmark.

Lisa Walther (L)

Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, University Hospital, Lund University, Lund, Sweden.

Anders Isaksson (A)

Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, University Hospital, Lund University, Lund, Sweden.

Peter Thind (P)

Department of Urology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Hanne Tønnesen (H)

WHO-CC, Clinical Health Promotion Centre, Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen University Hospitals, Copenhagen, Denmark; Clinical Health Promotion Centre, Health Sciences, Lund University, Lund, Skåne, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH